Objectives: Patients with cystic fibrosis (CF) are at constant risk for pulmonary colonization by opportunistic microorganisms. The black yeast, Exophiala dermatitidis, has consistently been isolated from patients with CF. The aim of this study was to determine the minimal inhibitory concentrations (MIC) for itraconazole, voriconazole, posaconazole, flucytosine and amphoterricin against E. dermatitidis. Methods: Since E. dermatitidis grows initially in the yeast form and acquires mould form with age, two methods i.e. the Clinical and laboratory Standards Institute (CLSI) for moulds and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for yeasts have been used. The results obtained from the two analytical systems were compared. Results: The overall agreement between CLSI and EUCAST was good (>90%), with the exception for posaconazole and flucytosine. Conclusion: The antifungal susceptibility testing of 53 clinical isolates, using CLSI and EUCAST shows that posaconazole was the most active drug against E. dermatitidis in vitro followed by voriconazole and itraconazole in both systems.